`Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
ALLHAT, the largest ever antihypertensiv e trial, compared cardiac outcomes in 42,418 high-risk individuals with mild-to-moderate hypertension, including 36% with diabetes, randomised to: 1) the thiazide-type diuretic, chlorthalidone; or 2) the ACE inhibitor, lisinopril; or 3) the calcium channel blocker, amlodipine. No differences between the groups were observed for the primary outcome coronary heart disease (CHD) but chlorthalidone was superior in preventing some cardiovascular disease events. Since diuretics are less expensive, it might be inferred that these drugs should be the preferred first-line antihypertensive therapy. However, the design and conduct of ALLHAT make interpretation of the results difficult. Despite its size, ALLHAT has few practical implications for management of hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Cited by
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Jones, D. W., & Hall, J. E. (2004) · Hypertension · doi:10.1161/01.hyp.0000110061.06674.ca · Cited by 309
Gupta, A. K., Dahlof, B., Dobson, J., Sever, P. S., Wedel, H., Poulter, N. R., & on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators (2008) · Diabetes Care · doi:10.2337/dc07-1768 · Cited by 146
Resistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Standl, E., Erbach, M., & Schnell, O. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2355 · Cited by 20
Metadata
- Authors
- Mcinnes, G. T.
- Venue
- The British Journal of Diabetes & Vascular Disease
- Publisher
- SAGE Publications
- Published
- 2003-07
- Volume
- 3
- Issue
- 4
- Pages
- 263-267
- ISSN
- 1474-6514 (ISSN-L)
- 1753-4305
- OpenAlex
- W2071333973
- Cited by
- 117
- References
- 5
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: `Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). https://app.cochat.ai/papers/10.1177/14746514030030040501
- The paper
- Mcinnes, G. T. (2003). `Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). The British Journal of Diabetes & Vascular Disease. https://doi.org/10.1177/14746514030030040501
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.